Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells $66,600.00 in Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Rosty Raykov sold 10,000 shares of the stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $6.66, for a total value of $66,600.00. Following the transaction, the director now directly owns 76,294 shares in the company, valued at approximately $508,118.04. This represents a 11.59 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Rosty Raykov also recently made the following trade(s):

• On Monday, January 6th, Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $6.08, for a total value of $60,800.00.
• On Thursday, December 5th, Rosty Raykov sold 796 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $6.04, for a total transaction of $4,807.84.

Fennec Pharmaceuticals Stock Down 1.9 %

Shares of FENC opened at $6.66 on Friday. The stock’s 50-day moving average price is $6.11 and its 200 day moving average price is $5.51. The firm has a market capitalization of $183.33 million, a price-to-earnings ratio of -66.59 and a beta of 0.34. Fennec Pharmaceuticals Inc has a 12-month low of $3.96 and a 12-month high of $11.49.

Fennec Pharmaceuticals (NASDAQ:FENC) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). The firm had revenue of $6.97 million for the quarter, compared to the consensus estimate of $9.13 million. Fennec Pharmaceuticals had a negative net margin of 2.30% and a negative return on equity of 53.38%. During the same quarter in the prior year, the firm posted ($0.07) earnings per share. Equities research analysts expect that Fennec Pharmaceuticals Inc will post -0.09 EPS for the current year.

Institutional Investors Weigh In On Fennec Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Advantage Alpha Capital Partners LP acquired a new position in shares of Fennec Pharmaceuticals in the 3rd quarter valued at $264,000. Barclays PLC raised its position in Fennec Pharmaceuticals by 274.3% in the third quarter. Barclays PLC now owns 31,319 shares of the company’s stock worth $157,000 after purchasing an additional 22,951 shares in the last quarter. Pinnacle Wealth Planning Services Inc. bought a new position in Fennec Pharmaceuticals during the fourth quarter worth about $97,000. The Manufacturers Life Insurance Company acquired a new stake in Fennec Pharmaceuticals during the second quarter valued at approximately $69,000. Finally, State Street Corp grew its stake in shares of Fennec Pharmaceuticals by 2.2% in the 3rd quarter. State Street Corp now owns 328,259 shares of the company’s stock valued at $1,641,000 after purchasing an additional 7,053 shares during the period. Institutional investors and hedge funds own 55.51% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on FENC shares. HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Fennec Pharmaceuticals in a research note on Tuesday, December 17th. Wedbush reaffirmed an “outperform” rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a research report on Friday, December 20th. Finally, Stephens raised Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 18th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.